Altimmune, Inc.

Altimmune is headquartered in the United States and its principal operations are managed from Maryland. The company has conducted clinical trials in the U.S. and other countries, and it notes that future trials may also occur in the United Kingdom, the European Union, or other foreign jurisdictions. Its reported consolidated entities include Altimmune UK, Ltd and Altimmune AU Pty, Ltd, indicating an international operating footprint even though the business remains U.S.-centered. Geography matters mainly because clinical development depends on regulatory approvals, site activation, patient enrollment, and supply-chain execution across jurisdictions. The company also highlighted tariff, inflation, and foreign-exchange-related uncertainty as factors that can affect operations and costs.

Altimmune faces the classic risks of a single-asset, late clinical-stage biotech company: trial failure, delayed enrollment, regulatory setbacks, and dependence on external financing. The company specifically notes that if it cannot maintain strategic partnerships for pemvidutide, it may have to bear the full cost and risk of development, which would pressure capital needs. It also faces operational risk from third-party vendors, foreign trial jurisdictions, and macro factors such as tariffs, inflation, supply-chain disruption, and capital-market volatility. More broadly, competition from much larger pharmaceutical companies could make it harder to recruit patients, secure manufacturing capacity, and ultimately commercialize a product if one is approved.